A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck Cancer (MONARCH)
8 de julio de 2013 actualizado por: Piramal Enterprises Limited
An Open Label, Multicenter Phase II Study to Evaluate Efficacy and Safety of P276-00 in Indian Subjects With Recurrent, Metastatic or Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck
This is a single arm phase II trial to study the efficacy and safety of a Cdk inhibitor P276-00 in the treatment of squamous cell carcinoma of head and neck.
Patients with recurrent or metastatic disease that is unresectable and incurable by radiation will be enrolled.
Thirty eight evaluable patients need to be enrolled in the study.
All patients will receive protocol treatment i.e.
P276-00 as an intravenous infusion from day 1 to day 5 and from day 8 to day 12 in each 21 day cycle till progression of disease or unacceptable toxicity.
Safety evaluations by means of recording vitals, physical examination and lab investigations like hematology and clinical chemistry will be undertaken at regular intervals in each cycle.
Tumor measurements by spiral CT scan will be undertaken at baseline and at the end of every 2 cycles for response evaluation by RECIST criteria.
All patients will be followed up for survival status till one year of cycle 1 day 1.
Descripción general del estudio
Estado
Terminado
Intervención / Tratamiento
Descripción detallada
P276-00 was administered at a dose of 185mg/m2/day from day 1 to day 5 in each 21 day cycle.
The protocol was amended in July 2009.
As per the amendment P276-00 will be administered at a dose of 144 mg/m2/day from day 1 to day 5 and from day 8 to day 12 in each 21 day cycle till progression of disease or unacceptable toxicity.33
patients have been recruited in version 1 protocol, 38 more evaluable patients need to be recruited in version 2 protocol.
Allowing for approximately 30% drop-outs, it is estimated that, for enrolling 38 evaluable subjects in the study, approximately 54 subjects would be enrolled.
As the study has already enrolled 33 subjects, the sample size for the study to accommodate for same number of subjects (38 evaluable) in the revised protocol is estimated as approximately 87 (33 + 54) subjects.
Hence the total sample size (accounting for drop-outs) is 87 patients.
Tipo de estudio
Intervencionista
Inscripción (Actual)
86
Fase
- Fase 2
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Karnataka
-
Mysore, Karnataka, India, 570017
- Bharath Hospital & Institute of Oncology, Mysore
-
-
Kerala
-
Trivandrum, Kerala, India, 695011
- Regional Cancer Centre
-
-
Maharashtra
-
Mumbai, Maharashtra, India, 400014
- Kashyap Nursing Home
-
Mumbai, Maharashtra, India, 400026
- Jaslok Hospital, Mumbai
-
Nagpur, Maharashtra, India, 440010
- Central India Cancer Research Institute,
-
Pune, Maharashtra, India, 411004
- Deenanath Mangeshkar Hospital & Research Centre
-
-
Rajasthan
-
Jaipur, Rajasthan, India, 302 017
- Bhagwan Mahaveer Cancer Hospital & Research Centre, Dept. Of Medical Oncology, Jaipur
-
-
Tamilnadu
-
Coimbatore, Tamilnadu, India, 641037
- V. N. Cancer Centre, GKNM Hospital,
-
-
UttarPradesh
-
Lucknow, UttarPradesh, India, 226003
- Dept. Of Surgical Oncology, CSM Medical University, Lucknow
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- Age more than or equal to 18 years
- Subjects with histologically or cytologically confirmed SCCHN that is recurrent and/or metastatic and judged incurable by surgery and/or radiation therapy and with zero to one line of chemotherapy for recurrent or metastatic disease at least 60 days prior to study entry.
- Measurable disease, defined as at least one unidimensionally measurable lesion ≥ 20 mm by conventional techniques or ≥10 mm by spiral computerized tomography (CT) scan or magnetic resonance imaging (MRI)
- Tumor that is accessible to biopsy
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- Life expectancy of at least three months
- Hemoglobin ≥ 8.0 gm/dL
- Absolute neutrophil count (ANC) ≥ 1000/mm3
- Platelet count ≥ 50,000/mm3
- Total bilirubin ≤1.5X institutional upper limit of normal (ULN)
- Serum AST ≤ 3X institutional ULN
- Serum ALT ≤ 3X institutional ULN
- Serum creatinine ≤1.5X institutional ULN
- Ability to understand and the willingness to sign a written informed consent document (ICD)
Exclusion Criteria:
- Nasopharyngeal carcinoma
- Prior treatment with P276-00 or other Cyclin dependent kinase (CDK) targeting agents
- History of allergic reactions attributed to compounds of similar chemical composition to P276-00
- Subjects who have received radiotherapy, chemotherapy or biologic/targeted anticancer agents within 60 days prior to Day 1 of study drug administration or have not recovered from adverse effects of any prior radiotherapy, chemotherapy or biologic/targeted agents.
- More than one chemotherapy regimen for the recurrent or metastatic disease
- Subjects who had received any other investigational drug within 1 month or within five half-lives of the other investigational agent, whichever is longer prior to Day 1 of study drug administration
- Subjects with QTc > 450 msec on 12 lead standard electrocardiogram (ECG)
- History of unstable angina or myocardial infarction or stroke within previous 6 months
- Subjects with uncontrolled inter-current illness including, but not limited to active infection, symptomatic congestive heart failure, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Subjects known to be suffering from infection with HIV, Tuberculosis, Hepatitis C or Hepatitis B
- Known brain metastasis
- History of prior malignancy except for curatively treated basal cell or squamous cell carcinoma of skin, in situ cervical cancer, in situ breast cancer, in situ prostate cancer or any other cancer for which the subject has been disease-free for at least 3 years
- Women who are pregnant or lactating
- Women of childbearing potential [defined as sexually mature women who have not undergone hysterectomy or who have not been naturally postmenopausal for at least 24 consecutive months (i.e. who have had menses any time in the preceding 24 consecutive months)] and men, not agreeing to use adequate contraception (e.g., hormonal or barrier method of birth control or abstinence) prior to study entry (after signing the ICD), during the period of study participation and for at least 4 weeks after withdrawal from the study, unless they are surgically sterilized
- Any condition, including laboratory abnormalities, that in the opinion of the Investigator places the subject at an unacceptable risk or deems the subject not suitable for participation in the study
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Single P276-00 arm
This is a single experimental arm study
|
For patients to be recruited in amended protocol, P276-00 will be administered to all subjects at a dose of 144 mg/m2/day as i.v infusion in 200 ml of 5% dextrose over 30 minutes from day 1 to day 5 and from day 8 to day 12 in each 21 day cycle.
Subjects will receive treatment till progression of disease or till unacceptable toxicity.
All subjects will be followed up for survival status till one year of initiation of protocol treatment.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Response rate
Periodo de tiempo: Tumor measurements to be undertaken at baseline and at the end of every 2 cycles. Response evaluation to be performed on the basis of RECIST criteria
|
Tumor measurements to be undertaken at baseline and at the end of every 2 cycles. Response evaluation to be performed on the basis of RECIST criteria
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Duration of response, Progression free survival (PFS), Time to progression (TTP), PFS at one year, Overall survival (OS) at one year
Periodo de tiempo: Tumor measurements at the end of every 2 cycles. Follow up for survival status every 4 weeks after discontinuation of protocol treatment till one year of cycle 1 day 1
|
Tumor measurements at the end of every 2 cycles. Follow up for survival status every 4 weeks after discontinuation of protocol treatment till one year of cycle 1 day 1
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Investigadores
- Investigador principal: Dr. Ajay Mehta, Director and Onco-Surgeon, Central India Cancer Research Institute, Nagpur
- Investigador principal: Dr. M S Vishveshwara, Radiation Oncologist, Bharat Hospital Institute of Oncology, Mysore
- Investigador principal: Dr. Sanjeev Misra, Oncosurgeon, Department of Surgical Oncology, CSM Medical University, Lucknow
- Investigador principal: Dr. Rejnish Kumar, Associate Professor, Regional Cancer Centre, Trivandram
- Investigador principal: Dr. Lalit Mohan Sharma, Consultant Medical Oncologist, Bhagwan Mahavir Cancer Hospital and Research Centre, Jaipur
- Investigador principal: Dr. Maheboob Basade, Medical Oncologist, Jaslok Hospital, Mumbai
- Investigador principal: Dr. Nilesh Lokeshwar, MD, DM, Medical oncologist
- Investigador principal: Dr. Chetan Deshmukh, MD, DM, Medical Oncologist, Deenanath Mangeshkar Hospital and Research Centre, Pune, India
- Investigador principal: Dr. M Nagarajan, MD, Radiation Oncologist, V. N. Cancer Centre, GKNM Hospital, Coimbatore, India
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de septiembre de 2008
Finalización primaria (Actual)
1 de abril de 2011
Finalización del estudio (Actual)
1 de junio de 2013
Fechas de registro del estudio
Enviado por primera vez
15 de enero de 2009
Primero enviado que cumplió con los criterios de control de calidad
15 de enero de 2009
Publicado por primera vez (Estimar)
16 de enero de 2009
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
10 de julio de 2013
Última actualización enviada que cumplió con los criterios de control de calidad
8 de julio de 2013
Última verificación
1 de julio de 2013
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- P276-00/21/08
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .